Knowthestock.com
INCY - Incyte Corp.
SNP 500

Hold

Strong Growth but Declining
WeakStrong
WeakStrong

74%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 8.87%
Operating Income Growth is 7.09%
Net Income Growth is 75.42%
Earnings Per Share (EPS) Growth is 74.34%
Net Margin is 16.17%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.75
Debt Ratio is 0.23
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is MODERATE
Cash from Operations Growth is -48.81%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Incyte Corp. (INCY) - https://www.incyte.com/
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Herve Hoppenot
Employees - 2,600
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.